LivaNova PLC (NASDAQ:LIVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $81.3750.

LIVN has been the subject of several recent analyst reports. Zacks Research upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. KeyCorp boosted their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Mizuho upped their target price on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $78.19 on Friday. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $85.27. The firm’s 50-day simple moving average is $78.31 and its 200 day simple moving average is $69.54. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The stock has a market cap of $4.29 billion, a P/E ratio of 40.10 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same quarter in the previous year, the business earned $0.88 earnings per share. The firm’s revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities analysts expect that LivaNova will post 3.73 EPS for the current year.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. This represents a 19.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.35% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Hantz Financial Services Inc. increased its stake in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the last quarter. State of Wyoming bought a new position in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its stake in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP acquired a new position in LivaNova during the third quarter valued at approximately $36,000. Finally, Covestor Ltd grew its holdings in LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.